Timothy John Garnett bought $253K of MapLight Therapeutics (MPLT)
Executed Feb 10, disclosed Feb 12, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 12), the stock returned +6.5% (delay-adjusted); from the execution session (Feb 10), +8.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Timothy John Garnett (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in MapLight Therapeutics, Inc. (MPLT). Across 1 priced purchase filing, the average 21-session return was +8.5% from execution and +6.5% from disclosure (delay-adjusted; derived). The largest single filing was $253K of MPLT (14,124 sh × $17.89, as filed), executed Feb 10.
Healthcare · MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→